ESMO 2022: PRESTO - A Phase 3 Androgen Annihilation in Biochemically Relapsed Prostate Cancer

By The Uromigos - Last Updated: September 11, 2022

Rahul Aggarwal describes the results of the randomized phase 3 PRESTO study that examined the effects of androgen suppressants on biochemically relapsed prostate cancer.

Post Tags:Uromigos-ESMO
Did you like this article?